HeartStart MRx, Rechargeable Li-Ion (lithium ion battery), REF: M3538A, which is a component of H...

FDA Device Recall #Z-0603-2019 — Class II — November 23, 2018

Recall Summary

Recall Number Z-0603-2019
Classification Class II — Moderate risk
Date Initiated November 23, 2018
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Philips North America LLC
Location Bothell, WA
Product Type Devices
Quantity 1880 Batteries

Product Description

HeartStart MRx, Rechargeable Li-Ion (lithium ion battery), REF: M3538A, which is a component of HeartStart MRx Monitor/Defibrillators.

Reason for Recall

Affected lithium-ion batteries may contain a defective component (Thermal Cut-off or TCO). Should the component fail, the battery will no longer charge or deliver power to the Monitor/Defibrillator, which may prevent operation of the device if it is not connected to AC or DC power. Should a second, unaffected battery be present in the Monitor/Defibrillator, the battery failure may go unnoticed.

Distribution Pattern

U.S.: AZ, WA, PA, UT, NY, CO, MD, AR, TX, MO, MI, FL, VA, MA, GA, TN, NV, OH, CA, NH, KY, KS, OR, WI, NC, IL, LA, NJ, WV, AL, WY, MS Foreign (OUS): United Kingdom, Korea Rep, Singapore, Australia, Taiwan, Sri Lanka, Brazil, France, Switzerland, Germany, Austria, Spain, Italy, Trinidad and Tobago, Estonia, Belgium, Portugal, Korea, Republic of, Argentina, India, Puerto Rico, Qatar, Netherlands, Mexico, South Africa, Ireland, Saudi Arabia, New Zealand, Bolivia, Costa Rica, Chile, Canada, Russian Federation, Slovenia

Lot / Code Information

UDI: (01)00884838002791; Serial Numbers: 17362-0001-P through 18057-0266-P

Other Recalls from Philips North America LLC

Recall # Classification Product Date
Z-1316-2026 Class II IQon Spectral CT; Product Code (REF): 728332; Jan 7, 2026
Z-1318-2026 Class II Spectral CT 7500 on Rails; Product Code (REF):... Jan 7, 2026
Z-1317-2026 Class II Spectral CT; Product Code (REF): 728333; Jan 7, 2026
Z-1315-2026 Class II Brilliance iCT; Product Code (REF): 728306; Jan 7, 2026
Z-1033-2026 Class II Philips Smart-hopping 2.0 AP 1.4 GHz. Patient M... Dec 12, 2025

Frequently Asked Questions

Contact your physician immediately if you use an electrical device or implant affected by this recall. For external devices (monitors, pumps), stop using the device and contact the manufacturer for a replacement. For implanted devices (pacemakers, ICDs), your cardiologist will assess whether you need device replacement surgery — the decision depends on how dependent you are on the device and the actual failure rate observed in the field. Do not attempt to repair or modify a recalled electrical medical device yourself. Monitor for any new or unusual symptoms and report them to your doctor.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.